论文部分内容阅读
为明确重组人生长激素能否有效治疗阿霉素肾病鼠骨病和生长障碍 ,将30只SD大鼠随机分为5组 :正常对照组、阿霉素肾病鼠组 (肾病组 )、地塞米松治疗的阿霉素肾病鼠组 (DXM组)、重组人生长激素治疗的阿霉素肾病鼠组 (rhGH组 )、地塞米松 +重组人生长激素治疗的阿霉素肾病鼠组 (DXM +rhGH组 ) ;测定各组的血清碱性磷酸酶、尿钙、尿磷、骨矿物质量、骨密度及鼻臀长的变化。结果显示 ,rhGH组的血清碱性磷酸酶水平明显高于其他4组 ,rhGH组和DXM +rhGH组活体椎骨骨矿物质的增长量及离体椎骨的骨密度明显高于肾病组和DXM组 ;而各组的24h尿钙、尿磷 ,全身骨的骨矿物质增长量 ,股骨、胫骨的骨密度 ,鼻臀长的增长量之间无明显差别。提示短期应用rhGH能有效治疗阿霉素肾病鼠骨病 ,但对其身长生长无显著影响。
In order to clarify whether recombinant human growth hormone can effectively treat adriamycin-induced rat’s bone disease and growth disorders, 30 SD rats were randomly divided into 5 groups: normal control group, adriamycin-induced nephropathy group (nephropathy group) (DXM group) treated with mitoxantrone, rhGH group treated with recombinant human growth hormone and DXM + group treated with recombinant human growth hormone rhGH group). The changes of serum alkaline phosphatase, urinary calcium, urine phosphorus, bone mineral density, bone mineral density and nasal buttock length were measured in each group. The results showed that the level of serum alkaline phosphatase in rhGH group was significantly higher than the other four groups. The amount of vertebral bone mineral and vertebral bone mineral density in rhGH group and DXM + rhGH group were significantly higher than that in nephropathy group and DXM group. However, there was no significant difference between the groups in terms of 24-h urinary calcium, urinary phosphate, total body bone mineral content, femur, tibia bone density and nasal buttock length. Prompt application of short-term rhGH can effectively treat doxorubicin-induced diabetic rat bone disease, but no significant effect on their growth.